Vanguard Group Inc. Buys 845,922 Shares of Kymera Therapeutics, Inc. $KYMR

Key Points

• Vanguard Group Inc. increased its stake in Kymera by 15.6%, buying 845,922 shares to hold 6,267,644 shares (about 8.71%) worth roughly $487.7 million.
• Kymera beat Q1 expectations: EPS was ($0.71) versus ($0.89) expected and revenue was $34.37 million (vs. $8.27M expected), a 55.5% year‑over‑year revenue gain.
• Analysts have raised targets and coverage (e.g., UBS to $128, Piper Sandler to $140, Jefferies initiating at $110), leaving a consensus rating of “Moderate Buy” with an average price target of $118.10.

Vanguard Group Inc. lifted its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 15.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,267,644 shares of the company's stock after acquiring an additional 845,922 shares during the quarter. Vanguard Group Inc. owned approximately 8.71% of Kymera Therapeutics worth $487,685,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its position in Kymera Therapeutics by 8.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 24,524 shares of the company's stock valued at $1,908,000 after purchasing an additional 1,992 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Kymera Therapeutics by 6.9% during the 4th quarter. Arizona State Retirement System now owns 13,284 shares of the company's stock worth $1,034,000 after purchasing an additional 853 shares in the last quarter. B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Kymera Therapeutics in the 4th quarter valued at approximately $1,214,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Kymera Therapeutics by 5.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,631 shares of the company's stock valued at $1,216,000 after buying an additional 789 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Kymera Therapeutics by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,496 shares of the company's stock valued at $272,000 after buying an additional 732 shares in the last quarter.

Analysts Set New Price Targets

KYMR has been the topic of a number of recent analyst reports. Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a report on Monday, March 16th. They set a "buy" rating and a $110.00 target price on the stock. UBS Group lifted their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a "buy" rating in a research report on Tuesday, March 3rd. Piper Sandler boosted their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an "overweight" rating in a research note on Thursday, February 26th. Canaccord Genuity Group assumed coverage on shares of Kymera Therapeutics in a research note on Wednesday. They issued a "buy" rating and a $106.00 target price for the company. Finally, BTIG Research lowered their price target on Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating on the stock in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Kymera Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $118.10.

Kymera Therapeutics Price Performance

KYMR stock opened at $82.71 on Wednesday. Kymera Therapeutics, Inc. has a fifty-two week low of $28.06 and a fifty-two week high of $103.00. The stock has a market capitalization of $6.80 billion, a price-to-earnings ratio of -23.17 and a beta of 2.06. The business's fifty day moving average price is $84.42 and its two-hundred day moving average price is $76.61.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company had revenue of $34.37 million during the quarter, compared to analysts' expectations of $8.27 million. During the same quarter in the previous year, the business posted ($0.82) earnings per share. Kymera Therapeutics's quarterly revenue was up 55.5% on a year-over-year basis. Research analysts expect that Kymera Therapeutics, Inc. will post -3.35 EPS for the current year.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera presented new preclinical data showing KT‑579 (oral IRF5 degrader) produced activity comparable or superior to approved/clinically active therapies in IBD models — a meaningful R&D positive if confirmed in clinical studies. Article Title
• Positive Sentiment: Management will participate in multiple May investor conferences (fireside chats), increasing visibility with investors and analysts — typically supportive for sentiment and liquidity. Article Title
• Positive Sentiment: Q1 results and the accompanying presentation prompted analysts to lift estimates in some reports and coverage; positive analyst reaction to quarterly revenue and beats can support the stock. Article Title
• Neutral Sentiment: Kymera published its Q1 earnings presentation (details on pipeline progress, financials and guidance assumptions), useful for investors but not an immediate catalyst by itself. Article Title
• Neutral Sentiment: Company celebrated its 10‑year anniversary and rang the Nasdaq opening bell — PR/branding event with limited direct impact on valuation. Article Title
• Negative Sentiment: Brookline Capital Markets issued multiple model changes: they raised some near‑ and long‑term estimates (e.g., FY2026, FY2028–FY2030) but lowered Q3/Q4 2026 and FY2027 forecasts — the mixed/downgrade elements could weigh on sentiment by signaling slower expected progress or higher near‑term spend. Article Title

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Noah Goodman sold 1,347 shares of the business's stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $90.00, for a total value of $121,230.00. Following the completion of the sale, the insider owned 50,195 shares of the company's stock, valued at $4,517,550. The trade was a 2.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $81.18, for a total transaction of $2,435,400.00. Following the transaction, the chief executive officer owned 666,195 shares in the company, valued at approximately $54,081,710.10. The trade was a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 380,734 shares of company stock worth $32,193,902 over the last quarter. Company insiders own 16.01% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.